Physician profile
Yeohan Song
NPI 1003279571
$1,431.20
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.55 · 2023: $381 · 2024: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.65 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $318.14 | 2023-2024 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $259.83 | 2023-2024 | |
| Janssen Biotech, INC. | $188.35 | 2024 | Tremfya |
| Abbvie INC. | $187.50 | 2023-2024 | Rinvoq, Skyrizi |
| Ucb, INC. | $123.51 | 2023-2024 | Cimzia |
| Ekos Corporation | $93.55 | 2019 | |
| Aurinia Pharma U.S., INC. | $63.33 | 2024 | Lupkynis |
| Lilly USA, LLC | $53.56 | 2024 | Taltz |
| Glaxosmithkline, LLC. | $47.57 | 2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $26.26 | 2024 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $24.90 | 2024 | Saphnelo |
| Insulet Corporation | $18.63 | 2024 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $13.77 | 2024 | Simlandi |
| Actelion Pharmaceuticals US, INC. | $12.30 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeohan Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.